GFH-925
- Generic Name
- GFH-925
- Drug Type
- Small Molecule
- Background
GFH-925 is an irreversibly covalent inhibitor of KRAS G12C.
A Study of GFH925 in Combination with Cetuximab in Previously Untreated Advanced NSCLC Harboring KRAS G12C Mutation
- Conditions
- Advance Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2023-03-06
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Genfleet Therapeutics (Shanghai) Inc.
- Target Recruit Count
- 45
- Registration Number
- NCT05756153
- Locations
- 🇮🇹
IRCCS Centro di Riferimento Oncologico, Aviano, Friuli-Venezia Giulia, Italy
🇪🇸Virgen del Rocio University Hospital, Sevilla, Spain
🇪🇸Hospital Regional Universitario de Malaga,Oncology Dept, Málaga, Spain
A Study of IBI351 in Healthy Subjects
- Conditions
- Healthy Subjects
- Interventions
- First Posted Date
- 2023-01-26
- Last Posted Date
- 2023-10-24
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT05699993
- Locations
- 🇨🇳
The First Affiliated Hospital of Suzhou University, Suzhou, Jiangsu, China
A Study of IBI351 in Healthy Subjects
- First Posted Date
- 2023-01-18
- Last Posted Date
- 2023-10-24
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT05688124
- Locations
- 🇨🇳
the First Affiliated Hospital of Suzhou University, Suzhou, Jiangsu, China
Efficacy and Safety of IBI351 in Combination With Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C Mutation
- Conditions
- Advanced Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2022-08-17
- Last Posted Date
- 2025-01-27
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 144
- Registration Number
- NCT05504278
- Locations
- 🇨🇳
Jilin Province Cancer Hospital, Jilin, Changchun, China
A Study of IBI351 in Combination With Cetuximab in Subjects With KRAS G12C Mutated Metastatic Colorectal Cancer
- First Posted Date
- 2022-08-11
- Last Posted Date
- 2022-09-30
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 80
- Registration Number
- NCT05497336
- Locations
- 🇨🇳
The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
A Study of GFH925 in Patients With Advanced Solid Tumors With KRAS G12C Mutations
- First Posted Date
- 2021-08-13
- Last Posted Date
- 2023-08-16
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 264
- Registration Number
- NCT05005234
- Locations
- 🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.